SILO Pharma (SILO) Ownership - Who owns SILO Pharma?

Key Takeaways

• Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on central nervous system (CNS) conditions, including PTSD, anxiety disorders, fibromyalgia, and multiple sclerosis.
• The company's lead program, SPC-15, is an intranasal therapeutic candidate targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders.
• SILO develops both conventional drugs and psychedelic-based formulations, including ketamine and psilocybin-based approaches.
• As a development-stage business, Silo Pharma generates minimal revenue and has reported net losses, which is typical for early-stage drug developers.
• Investors follow SILO primarily for its clinical pipeline and potential future regulatory milestones rather than current earnings.

Introduction

Silo Pharma, Inc. (SILO) is a development-stage biopharmaceutical company traded on the Nasdaq Capital Market. The company is working to develop novel therapeutics for underserved conditions affecting the central nervous system (CNS), including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and neurological diseases. As an early-stage drug developer with a pipeline still in preclinical and early clinical stages, Silo Pharma has not yet commercialized a product and generates little to no revenue. Investors who follow the ticker are generally focused on the long-term potential of its drug candidates and any progress toward regulatory approval.

Company Overview and History

Silo Pharma was incorporated in the state of New York on July 13, 2010. The company subsequently reincorporated in Delaware in 2013 and, in December 2023, changed its state of incorporation to Nevada. Its principal executive offices are located in Sarasota, Florida. The company operates as a small organization, consistent with its development-stage status.

The company's business model centers on identifying, licensing, and advancing therapeutic assets that address unmet medical needs, with a particular emphasis on treatments for mental health conditions and neurological disorders. Silo Pharma has stated that it seeks to acquire and develop intellectual property and technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs such as psilocybin and ketamine for depression, mental health issues, and neurological disorders.

Pipeline and Core Programs

Silo Pharma's financial profile and market position are tied closely to its investigational pipeline rather than to marketed products. The company's lead program, SPC-15, is an intranasal prophylactic being developed for PTSD and stress-induced anxiety disorders. The company has described plans to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical testing.

Beyond SPC-15, the company's pipeline includes:

• SP-26, a time-release, ketamine-based implant being developed for fibromyalgia and chronic pain relief.
• SPC-14, a preclinical intranasal compound targeting Alzheimer's disease.
• SPU-16, a CNS-homing peptide targeting the central nervous system, with an initial research indication in multiple sclerosis (MS).

Because these candidates are largely in preclinical or early clinical stages, the company's primary revenue sources are minimal, consisting of limited licensing revenue. It relies on equity financing and other capital-raising activities to fund its research and operations.

Why Investors Follow SILO

Investor interest in Silo Pharma is driven primarily by the long-term potential of its pipeline, particularly its focus on PTSD and other mental health conditions where existing treatment options can be limited. The company's emphasis on psychedelic and alternative drug formulations positions it within an emerging segment of biopharmaceutical research that has drawn growing scientific and commercial attention.

The company's intranasal delivery approach for SPC-15 and its ketamine-based implant for SP-26 represent differentiated mechanisms that could, if successfully developed and approved, offer novel treatment options. However, because the company has not yet brought a product to market, any investment thesis depends heavily on future clinical trial results and regulatory milestones.

Risks and Important Considerations

Investing in Silo Pharma carries substantial risks typical of development-stage biopharmaceutical companies. The company has reported net losses and has no approved products, meaning its ability to generate meaningful revenue depends on the success of clinical trials that may take years and may ultimately fail.

Key risks include:

• Clinical and regulatory risk: Drug candidates must pass rigorous clinical trials and FDA review, with no guarantee of approval.
• Financing risk: As an early-stage company with minimal revenue, Silo Pharma may need to raise additional capital, which can dilute existing shareholders.
• Competition: The CNS and mental health treatment space is competitive, with larger pharmaceutical companies and other biotechs pursuing similar indications.
• Operational scale: With a very small workforce, the company has limited internal resources relative to larger competitors.
• Psychedelic regulatory complexity: Therapies involving controlled substances such as ketamine and psilocybin face additional legal and regulatory considerations.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. For those seeking to broaden their research beyond a single ticker, exploring the AI Screener can help uncover additional candidates aligned with a particular investing approach.

Conclusion

Silo Pharma is a small, development-stage biopharmaceutical company focused on CNS conditions, with a lead candidate targeting PTSD and a broader pipeline spanning anxiety, fibromyalgia, Alzheimer's disease, and multiple sclerosis. Its use of both conventional and psychedelic-based drug formulations distinguishes it within an emerging area of research. For investors, the ticker represents early-stage, high-risk exposure to a clinical pipeline rather than an established commercial business, making its long-term relevance dependent on future clinical and regulatory developments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations